NCT03310879招募中2 期
A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 38
- 试验地点
- 2
- 主要终点
- Progression-Free Rate
研究概览
简要总结
This research study is studying a targeted therapy as a possible treatment for cancer abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6.
The drug involved in this study is:
-Abemaciclib
详细描述
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved Abemaciclib as a treatment for any disease.
To participate in this study, the participant must have an abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6. Abnormalities in these genes may cause the cancer to grow more rapidly. CDK4 and CDK6 are proteins that are involved with the cell growth process. D-type cyclins (CCND1, CCND2, and CCND3) are proteins that help control the activity of CDK4 and CDK6.
Abemaciclib is being studied as a treatment for people with advanced cancer. Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth. In this research study, the investigators are hoping to learn whether Abemaciclib can be used to slow or stop the growth of cancers with specific genetic abnormalities.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must have a histologically or cytologically confirmed advanced solid tumor of a non-breast origin, for which standard therapy proven to provide clinical benefit does not exist or is no longer effective.
- •For enrollment to Arm 1: Participants must have a confirmed CCND1, 2, or 3 high-level amplification, CCND1 mutation, or a CCND1 splice variant expected to lead to nuclear retention of cyclin D1 protein, via DFCI/BWH OncoPanel or any CLIA-certified method.
- •For enrollment to Arm 2: Participants must have a confirmed CDK4 or CDK6 high-level amplification, identified via DFCI/BWH OncoPanel or any CLIA-certified method.
- •Participants must have evaluable or measurable disease.
- •Age ≥ 18 years.
- •ECOG performance status of 0-1 (see APPENDIX A).
- •Participants must have normal organ and marrow function as defined below:
- •Absolute neutrophil count ≥1,500/mcL
- •Platelets ≥100,000/mcL
- •Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN)
- •AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional (ULN) -OR-
- •AST(SGOT)/ALT(SGPT) ≤ 5 × institutional (ULN) if liver metastases are present
- •Serum Creatinine ≤ 1.5 × institutional ULN -OR-
- •Creatinine clearance ≥ 60 mL/min (Cockroft-Gault Equation)
- •The effects of abemaciclib on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 3 months after completion of abemaciclib administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. A negative serum pregnancy test is required for women of childbearing potential prior to study entry.
- •Ability to understand and the willingness to sign a written informed consent document.
- •Ability to swallow and retain oral medication.
排除标准
- •Participants who have had chemotherapy, biologic therapy, investigational agents, radiotherapy, or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study.
- •Participants who have had oral targeted therapy or oral tyrosine kinase inhibitors (TKIs) within 5 half-lives prior to entering the study.
- •Participants who have received prior treatment with a CDK4/6 inhibitor.
- •Participants must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the study.
- •Participants who are receiving any other investigational agents.
- •Participants with hematologic lymphoma.
- •Participants with symptomatic CNS metastases who are neurologically unstable and/or require radiation therapy are excluded.
- •Participants with brain metastases that do not meet the above criteria in the opinion of the treating investigator are allowed.
- •Symptomatic disease is allowed as long as symptoms are controlled and stable.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to abemaciclib.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant women are excluded from this study because abemaciclib is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with abemaciclib, breastfeeding should be discontinued if the mother is treated with abemaciclib. A negative serum pregnancy test is required for women of childbearing potential prior to study entry.
- •Participants with known HIV-positive status are ineligible because these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
- •Participants with known active Hepatitis B or Hepatitis C.
- •Participants receiving an enzyme-inducing antiepileptic drug (EIAED) who cannot be transferred to a non-EIAED (e.g., levetiracetam, lacosamide, lamotrigine, etc.) prior to the initiation of protocol therapy.
研究组 & 干预措施
Participants with CCND1, CCND2, or CCND3
Experimental
- Abemaciclib will be administered orally on a daily basis
- Dosage will be determine by the PI
干预措施: Abemaciclib (Drug)
Participants with CDK4 or CDK6
Experimental
- Abemaciclib will be administered orally on a daily basis
- Dosage will be determine by the PI
干预措施: Abemaciclib (Drug)
结局指标
主要结局
Progression-Free Rate
时间窗: 4 months
proportion of patients who are alive and progression-free at 4 months on both arms.
次要结局
- Overall Response Rate(2 years)
- Toxicity(2 years)
- Adverse events by CTCAE 4.03(2 years)
研究者
Geoffrey Shapiro, MD, PhD
Principal Investigator
Dana-Farber Cancer Institute
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLCSmall-cell Lung CancerLarge Cell Neuroendocrine Carcinoma of the LungExtrapulmonary Small Cell CarcinomaNCT04010357Case Comprehensive Cancer Center14
暂停
1 期
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsLung Cancer Squamous CellSolid TumorsHead & Neck CancerPancreatic CancerNCT03065062Dana-Farber Cancer Institute75
招募中
1 期
A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6iInhibition of Autophagy Synergizes Anti-tumor EffectNCT05953350Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University29
招募中
1 期
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerCastration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Metastatic Castration-resistant Prostate CarcinomaMetastatic Castration-resistant Prostate CancerNCT05113537Vadim S Koshkin30
已完成
1 期
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerLung CancerNCT03170206Dana-Farber Cancer Institute34